Evidence map›Paper›PMID 19688297›Full record

Trial reportJournal of neuro-oncology2010

Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide.

Gregor Dresemann, Michael Weller, Mark A Rosenthal, Ulrich Wedding, Wolfgang Wagner, Erik Engel, Bernhard Heinrich, Regine Mayer-Steinacker, Anders Karup-Hansen, Oystein Fluge and 11 more

Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 9 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 9 syntheses or guidelines pooled it, 153 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Incorporation of biomarkers in phase II studies of recurrent glioblastoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Article
  19. Review
  20. Glioblastoma Therapy: Past, Present and Future.International journal of molecular sciences · 2024
    Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 7 countries.

Gregor DresemannZentrum für Neuro-Onkologie am Arztehaus Velen, Ignatiusstrasse 8, 46342, Velen, Germany. gdresemann@aol.com
Michael Weller
Mark A Rosenthal
Ulrich Wedding
Wolfgang Wagner
Erik Engel
Bernhard Heinrich
Regine Mayer-Steinacker
Anders Karup-Hansen
Oystein Fluge
Anna Nowak
Maximilian Mehdorn
Eberhard Schleyer
Dietmar Krex
Ian N Olver
Joachim P Steinbach
Christian Hosius
Christian Sieder
Greg Sorenson
Richard Parker
Zariana Nikolova
Novartis (Switzerland) · CHPraxis für Hämatologie und Onkologie · DEUniversity of Tübingen · DECancer Council Australia · AUHaukeland University Hospital · NOHerlev Hospital · DKJena University Hospital · DEKlinikum Coburg · DEMassachusetts General Hospital · USParacelsus-Kliniken · DESir Charles Gairdner Hospital · AUThe Royal Melbourne Hospital · AUUniversity and Rehabilitation Clinics Ulm · DEUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A randomized, multicenter, open-label, phase 3 study of patients with progressive, recurrent glioblastoma multiforme (GBM) for whom front-line therapy had failed was conducted. This study was designed to determine whether combination therapy with imatinib and hydroxyurea (HU) has superior antitumor activity compared with HU monotherapy in the treatment of recurrent GBM. The target population consisted of patients with confirmed recurrent GBM and an Eastern Cooperative Oncology Group performance status of 0-2 who had completed previous treatment comprising surgical resection, irradiation therapy, and first-line chemotherapy (preferably temozolomide (TMZ) containing regimen) and who have progressed despite treatment. If first-line chemotherapy did not contain TMZ, a second completed chemotherapy was acceptable. The primary efficacy parameter was progression-free survival (PFS). The primary comparison of combination therapy versus monotherapy for PFS was not significant (adjusted P = 0.56). The hazard ratio (HR) (adjusted HR = 0.93) was not clinically relevant. The median PFS for the combination arm was low at 6 weeks and similar to the median PFS in the monotherapy arm (6 weeks). The 6-month PFS for the two treatment groups was very similar (5% in the combination arm vs. 7% in the monotherapy arm). No clinically meaningful differences were found between the two treatment arms, and the primary study end point was not met. Among the patients receiving imatinib, no adverse events were reported that were either previously unknown or unexpected as a consequence of the disease.

Indexed as

AdultAgedAge FactorsAntineoplastic AgentsAntineoplastic Agents, AlkylatingBenzamidesBrain NeoplasmsCombined Modality TherapyDacarbazineDisease-Free SurvivalFemaleGlioblastomaHumansHydroxyureaImatinib MesylateMaleAntineoplastic AgentsAntineoplastic Agents, AlkylatingBenzamidesDacarbazineHydroxyureaImatinib MesylatePiperazinesPyrimidinesTemozolomide

Identifiers

PMID19688297
OpenAlexW1965157625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.